Drug Profile
Mizoribine - Asahi Kasei Pharma Corp
Alternative Names: Bredinin; HE-69Latest Information Update: 21 Jun 2019
Price :
$50
*
At a glance
- Originator Asahi Kasei
- Developer Asahi Kasei; Asahi Kasei Pharma Corp; Chong Kun Dang
- Class Antirheumatics; Ribonucleosides; Small molecules
- Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Lupus nephritis; Nephrotic syndrome; Renal transplant rejection; Rheumatoid arthritis
Most Recent Events
- 01 Mar 2019 Asahi Kasei Pharma completes a phase III trial in Lupus nephritis in China (PO) (NCT02256150)
- 01 Nov 2018 Asahi Kasei completes a phase III trial for Nephrotic syndrome (Treatment-resistant) in China (NCT02257697)
- 06 Feb 2017 Mizoribine is still in phase III trials for Nephrotic syndrome (Treatment-resistant) and Lupus nephritis in China (PO)